Research Options: Select below IPO Calendar	Week of Expected Pricing Pending Company Name BIOCANCELL LTD Proposed Ticker ANCN CUSIP N/A Business Description A clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard treatment for early-stage bladder cancer, which is one of the most prevalent forms of cancer. Lead Underwriter Oppenheimer & Co Co-Managers Ladenburg Thalmann & Co. Inc Initial Shares N/A Revised Initial Shares N/A Initial Price N/A Revised Price N/A Final Price N/A Final Ticker N/A
	© 2024 ICE Data Services. All rights reserved.